Alexion Hero Image


Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases. We discovered and developed the first and only approved complement inhibitor for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, our two highly innovative enzyme replacement therapies treat the life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

121 Seaport Blvd

Boston, MA 02210


+1 (203) 272-2596